⚡️ On European Urology - European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines #BladderCancer europeanurology.com/article/S0302-…

This is the table we’ve used (common AEs & dose⬇️) for Afatinib, Osimertinib, and Amivantamab + Lazertinib #ToxCheck 🗣️ on commonly used anti-EGFRs in mEGFR NSCLC w/ gilberto lopes #lcsm #OncTwitter #MedTwitter

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

Lu-177 DOTATATE PRRT in patients with NETs and extensive bone metastases. Is it effective and is it safe? It looks like the answer is yes to both and indeed, we use it frequently under such circumstances. Skeletal related events were 20%... jnm.snmjournals.org/content/early/…

Optimizing Breast Cancer Radiation therapy With Volumetric Modulated Arc Therapy and Skin Flash: A Case Study Using Deep Inspiration Breath Hold and Cherenkov Imaging - Advances in Radiation Oncology advancesradonc.org/article/S2452-…

🔥Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up🔥 Annals of Oncology doi.org/10.1016/j.anno… 👉Important updates on the treatment of rectal cancer 👉Multiple options and strategies ESMO - Eur. Oncology

Renal cancer #ASCO25 1) Casdatifan/carbo phase 2 data (RR=41%) ⏩️ R3 PEAK1 2)Biomarkers from sequential tissue from adjuvant atezo study IM010 3) CAR-T (CD70) data cRR20% 4) Final analysis for ipi/nivo ITT (HR 0.71) 5) predicting response to Cabo/nivo from TME & Microbiome

Bladder cancer #ASCO25 1) Ipi/nivo vs 1st line chemo (HR 0.79)-near miss 2) maintenance SG/PD-L1 vs PD-L1 (PFS HR0.49)-still relevant? 3) CIS subset analysis for salanlimab in NMIBC-pt selection for therapy? 4) A new Nectin4 ADC 9MW/PD1 in phase II RR=88%! 5) EVP update on RR/tox

Efficacy and Safety of Metastatic Directed Treatment of Oligometastatic Disease: Results of a Meta-analysis - Advances in Radiation Oncology advancesradonc.org/article/S2452-…

📘Management of testicular cancer JCO Oncology Practice ASCO 👉doi.org/10.1200/OP-25-… OncoAlert #cancer #oncology #MedX

PARP inhibitors in ovarian cancer: A timeline of rise & retreat! Journal of Clinical Oncology U.S. FDA FDA Oncology OncoAlert Oncology Brothers doi.org/10.1200/JCO-24…

⚡️ The CHMP recommends EU approval of perioperative durvalumab for muscle-invasive bladder cancer, based on phase 3 NIAGARA trial data. 🔹 Significant improvement in event-free survival 🔹 First perioperative immunotherapy for MIBC in Europe 🔹 A potential shift in standard of

Ready for #ASCO25? Here are the plenary highlights👇 1️⃣ #ATOMIC Ph. III (Alliance A021502) in early‐stage III dMMR colon CA, where adj mFOLFOX6 goes head-to-head with the same chemo + atezo. Prim endpoint is DFS, sec are OS + AEs. So far, no interim data—all eyes on this one!

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage 🔹 Low-risk: Active surveillance; avoid ADT 🔹 Intermediate-risk: Surgery or RT; ADT case-based 🔹 High-risk: Surgery/RT + long-term ADT #EAUguidelines #ProstateCancer Download Cheat Sheet here: uroweb.org/guidelines/pro…

🌟 Adjuvant Therapy in Renal Cancer 👨‍⚕️ Presented by Javier Molina Cerrillo #GUARDSymposium2025 OncoAlert 📌 Current status: ▪️ Pembrolizumab (KN564) = approved, DFS+ but OS data immature ▪️ CheckMate 914 & PROSPER = negative ▪️ No predictive biomarkers ▪️ Ongoing: RAMPART, LITESPARK-022

🌟 Terapia Adyuvante en Cáncer Renal 👨‍⚕️ Presentado por Javier Molina Cerrillo #GUARDSymposium2025 OncoAlert 📌 Panorama actual: ▪️ Pembrolizumab (KN564) aprobado, mejora en SLE pero SG inmadura ▪️ CheckMate 914 y PROSPER: resultados negativos ▪️ Sin biomarcadores predictivos ▪️ En curso:

🌟🔵 Systemic Treatment Intensification in mHSPC 👨‍⚕️ Presented by Dr. Gerhardt Attard #GUARDSymposium2025 OncoAlert 🔹 Extended lymphadenectomy may improve MFS, not BCR (NS trend) 🔹 SPCG-15: RP ±RT vs RT±TPA → Primary endpoint: cancer-specific survival 🔹 PROTEUS: Apalutamide

🌟🎓✔️🖋MUST READ Key Updates in Testicular Cancer: Optimizing Survivorship and Survival 👨‍⚕️ Authors: Dr. Lawrence Einhorn DrBagrodia Ragnhild Hellesnes Lucia Nappi Sia Daneshmand, M.D. University of British Columbia  Testicular Cancer Society IU School of Medicine Indiana University Department of Urology  IU Simon Comprehensive Cancer Center OncoAlert 🔹 Testicular cancer: high

Updated results from KEYNOTE-B61: First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows: ✅ ORR 51% ✅ CR in 8.2% ✅ Median DOR 19.5 mo A promising option for nccRCC. #oncology #kidneycancer European Urology Laurence Albiges OncoAlert Uromigos pubmed.ncbi.nlm.nih.gov/40707309/

This is the table we’ve used (common AEs, black📦warnings, & dose⬇️) during our discussion for #Lenvatinib, #Cabozantinib, #Axitinib, #Tivozanib #Belzutifan in RCC w/ Sumanta K. Pal, MD, FASCO #OncTwitter #gusm #MedTwitter OncoAlert OncUpdates